DiogenX Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $6.98M

  • Investors
  • 10

DiogenX General Information

Description

Operator of a biotechnology platform intended to regenerate insulin-producing beta cells for the treatment of diabetes. The company offers recombinant proteins that modulate the signalling pathway to regenerate functional pancreatic islets to prevent pancreatic beta-cell degradation and rebalance glucose or insulin homeostasis, enabling individuals with Type 1 glucose disregulation disorder to restore natural insulin production.

Contact Information

Website
www.diogenx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 180 avenue du Prado
  • 13008 Marseille
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 180 avenue du Prado
  • 13008 Marseille
  • France

DiogenX Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DiogenX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 31-Dec-2024 $6.98M Completed Generating Revenue
3. Grant 02-Mar-2023 Completed Generating Revenue
2. Early Stage VC (Series A) 01-Mar-2023 $29.5M $34.5M Completed Pre-Clinical Trials
1. Seed Round 16-Jun-2020 $5.01M $5.01M Completed Pre-Clinical Trials
To view DiogenX’s complete valuation and funding history, request access »

DiogenX Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Seed
To view DiogenX’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

DiogenX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to regenerate insulin-producing beta cells for the treatment of diabetes.
Drug Discovery
Marseille, France
9 As of 2022

Germantown, MD
 

Lyon, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DiogenX Competitors (2)

One of DiogenX’s 2 competitors is Orgenesis, a Corporation company based in Germantown, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Orgenesis Corporation Germantown, MD
Poxel Formerly VC-backed Lyon, France
You’re viewing 2 of 2 competitors. Get the full list »

DiogenX Patents

  • 10

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 7

    Pending

  • Expiring in next 12 mo

DiogenX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024210262-A1 Recombinant variants of r-spondin proteins and their use Pending 19-Jan-2023
EP-4652188-A1 Recombinant variants of r-spondin proteins and their use Pending 19-Jan-2023
WO-2024153764-A1 Recombinant variants of r-spondin proteins and their use Inactive 19-Jan-2023
AU-2022311529-A1 Recombinant variants of r-spondin proteins and their use Pending 15-Jul-2021
CA-3225626-A1 Recombinant variants of r-spondin proteins and their use Pending 15-Jul-2021 C07K14/4702
To view DiogenX’s complete patent history, request access »

DiogenX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DiogenX Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
European Innovation Council Accelerator/Incubator Minority
Horizon Europe Not-For-Profit Venture Capital
Inserm Transfert VC-Backed Company Minority
Lilly USA Corporation Minority
Omnes Capital PE/Buyout Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

DiogenX FAQs

  • When was DiogenX founded?

    DiogenX was founded in 2020.

  • Where is DiogenX headquartered?

    DiogenX is headquartered in Marseille, France.

  • What is the size of DiogenX?

    DiogenX has 9 total employees.

  • What industry is DiogenX in?

    DiogenX’s primary industry is Drug Discovery.

  • Is DiogenX a private or public company?

    DiogenX is a Private company.

  • What is the current valuation of DiogenX?

    The current valuation of DiogenX is .

  • What is DiogenX’s current revenue?

    The current revenue for DiogenX is .

  • How much funding has DiogenX raised over time?

    DiogenX has raised $41.4M.

  • Who are DiogenX’s investors?

    European Innovation Council, Horizon Europe, Inserm Transfert, Lilly USA, and Omnes Capital are 5 of 10 investors who have invested in DiogenX.

  • Who are DiogenX’s competitors?

    Orgenesis and Poxel are competitors of DiogenX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process